Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

NINTEDANIB ESYLATE vs NIRSEVIMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

NINTEDANIB ESYLATE vs NIRSEVIMAB: Safety Overview

Metric NINTEDANIB ESYLATE NIRSEVIMAB
Total FAERS Reports 117 247
Deaths Reported 23 5
Death Rate 19.7% 2.0%
Hospitalizations 39 149
Average Patient Age 66.4 yrs 0.3 yrs
% Female Patients 47.8% 42.3%
FDA Approval Date Oct 15, 2014 N/A
Manufacturer Boehringer Ingelheim Pharmaceuticals,... Sanofi Pasteur Inc.
Route ORAL INTRAMUSCULAR
Marketing Status Prescription N/A